Opinion|Videos|February 4, 2025
Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis
Panelists provide an overview of the latest efficacy and safety data for IL-13–targeting therapies in atopic dermatitis (AD), including recently presented data on dupilumab, lebrikizumab, and tralokinumab, focusing on their effectiveness in symptom reduction and safety profiles across patient populations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please give an overview of latest efficacy and safety data with IL-13–targeting therapies in AD, including recently presented data.
- Dupilumab
- Lebrikizumab
- Tralokinumab
Advertisement
Related to this article
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
3
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5